Atopic dermatitis is a common disease known to disproportionately impact minorities in a variety of ways. Improving access to care and increasing clinical training can help reduce barriers for underserved populations.

Host: Payel Gupta, MD, FACAAI;  Experts: Andrew Alexis, MD, MPH, Marcella Aquino, MD, FACAAI, FAAAAI, Anil Nanda, MD, FACAAI, FAAAAI, FACP Disclosures

To download the mp3 file, right click on the player and select Save audio as.

Interested in claiming CME for this episode? Click here

Resources

Speaker Disclosures back to top

All relevant financial relationships with ineligible companies have been mitigated.

Andrew Alexis, MD, MPH | Grants: Leo, Novartis, Almirall, Bristol-Myers-Squibb, Amgen, Menlo, Galderma, Valeant (Bausch Health), Cara, Arcutis, Dermavant |  Advisory Board: Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdof, Valeant, L'Oreal, BMS, Bausch Health, UCB, Vyne, Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel, Amgen, VisualDx, Eli Lilly, Swiss American | Speaker: Regeneron, SANOFI-Genzyme, Pfizer, BMS | Royalties: Springer, Wiley-Blackwell, Wolters Kluwer Health

Payel Gupta, MD, FACAAI | Advisor, Speaker: ALK

Marcella Aquino, MD, FACAAI, FAAAAI | No financial relationships with ineligibile companies to disclose.

Anil Nanda, MD, FACAAI, FAAAAI, FACP | No financial relationships with ineligible companies to disclose.

This podcast series is supported by Pfizer.